

# SCADA Replacement Aventis Pharmaceuticals UK



safety solutions

oil & gas

pharmaceutical

nuclear

power & utilities



**AUSTRALIA**

**Newcastle (Head Office)**

Ph +61 2 4941 1211  
 Fx +61 2 4954 3543  
 headoffice@serck-controls.com

**Perth**

Ph +61 8 9344 9000  
 Fx +61 8 9344 4620  
 perth@serck-controls.com

**UNITED KINGDOM**

**Coventry**

Ph +44 24 7630 5050  
 Fx +44 24 7630 2437  
 uk@serck-controls.com

**Serck Control and Safety Ltd**

**Luton**

Ph +44 15 8250 9900  
 Fx +44 15 8250 9901  
 safety@serck-controls.com

**MIDDLE EAST**

**Dubai**

United Arab Emirates  
 Ph +971 4 883 4083  
 Fx +971 4 883 4084  
 middleeast@serck-controls.com

**Background**

Aventis Pharmaceuticals UK Ltd., part of the global Aventis group, produces prescription drugs for serious diseases such as Arthritis, Respiratory Disease and Cancer.

**System Description**

The Aventis SCADA replacement project was initiated by Aventis due to the lack of 21 CFR 11 compliance and general age of three DOS based SCADA systems they had been using on several large manufacturing processes. Serck were chosen to undertake the work for their proven track record with Aventis of providing high quality, cost effective solutions and significant pharmaceuticals experience.

Our scope of supply was the design, development and commissioning of three new SCADA systems designed to interface to the existing Omron C200HS PLCs and provide a similar look and feel to the existing system. Each of the systems also incorporated a new 21CFR11 compliant Batch Reporting.

The initial design stages of the project involved developing format specifications for each of the three systems based on interrogation of the existing SCADA system configuration. Once the SCADA and batch reporting system were implemented, testing of the system was conducted at Serck against detailed test specifications developed from the existing configuration. Testing in this manner provided additional assurance of the accuracy of the new implementation before delivery to site as it was not possible once the system was installed to fully exercise all I/O.

Budget and delivery aspirations were fully met.

**Features**

- Batch Reporting
- Common User Functionality

**Benefits**

- Full FDA 21CFR11 Compliance
- Fully Validated
- Improved User Interface
- Increased Reliability